Journal
NATURE MEDICINE
Volume 22, Issue 2, Pages 128-134Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4036
Keywords
-
Funding
- National Cancer Center
- US National Cancer Institute [R01CA172152, R01CA113794]
- Garrett B. Smith Foundation
- Cure AT/RT Now foundation
- Avalanna Fund
- Miles for Mary
Ask authors/readers for more resources
Recent genomic studies have resulted in an emerging understanding of the role of chromatin regulators in the development of cancer. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex, is recurrently mutated in several forms of cancer and is highly expressed in numerous others. Notably, both gain-of-function and loss-of-function mutations occur in cancers but are associated with distinct cancer types. Here we review the spectrum of EZH2-associated mutations, discuss the mechanisms underlying EZH2 function, and synthesize a unifying perspective that the promotion of cancer arises from disruption of the role of EZH2 as a master regulator of transcription. We further discuss EZH2 inhibitors that are now showing early signs of promise in clinical trials and also additional strategies to combat roles of EZH2 in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available